GEORGETOWN UNIVERSITY ADULT AIDS CLINICAL TRIALS UNIT

乔治敦大学成人艾滋病临床试验单位

• 批准号: 3547983
• 负责人: PHILLIP F PIERCE
• 金额: $ 70.4万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-04-01 至 1996-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3547983
• 关键词: AIDS; AIDS therapy; clinical trials

A Georgetown University (GU) ACTU will provide HIV-related clinical trials to the diverse Washington DC community, which has the fifth highest number of AIDS cases, and the second highest prevalence of HIV-infected women of childbearing age in the nation. The GU ACTU is committed to the full participation of women and minorities in clinical trials, and the rigorous investigation of scientific issues impacting HIV drug protocols. As the demographics of the AIDS epidemic have changes, HIV-related clinical trials at GU have increasingly represented African -Americans (52%), IVDUs and women (21%). DC General Hospital and Whitman Walker Clinic will be ACTU subunits, providing increased access to under served patient populations and the ability to offer primary care to all study patients, thereby encouraging recruitment and retention. The subunits are anticipated to enroll 33% of our proposed 150 patients per year. The treatment of HIV lymphoma is an area of special emphasis at GU; the development and application of new chemotherapeutic approaches to HIV associated malignancies will be studied. Maryland Medical Laboratory, Inc, an ACTG approved laboratory, will be responsible for the virology core component. Optional study applications are submitted in the areas of pharmacology, epidemiology and immunology. The pharmacology core support lab has proposed an investigation of factors responsible for adverse drug effects and interactions including genetic and metabolic predictors. A project proposed under C.6 funding will evaluate the influence of psychosocial, biological and medical care factors on adherence and retention in clinical trials, addressing an issue that could affect recommendations for trial designs involving disadvantaged or under-served populations. On-going work in immunology on the control of Mycobacterium avium intracellulare will be extended, focusing particularly on the importance of NK cell function. Data from the optional components will have implications for therapeutics and trial design. Collaboration has been established with the VA Hospital's CPCRA Site, and the HRSA HIV Demonstration project. They will participate with GU and Howard University Medical Center in a combined community outreach program to educate under-represented groups to the advantages and importance of their participation in clinical trials. The Georgetown ACTU application is representative of the expertise existing in Washington, the diversity of our community, and scientific inquiry of a major University Medical Center.

乔治敦大学（GU）ACTU将提供与HIV相关的临床试验 对于多元化的华盛顿特区社区，该社区的数量最高第五 艾滋病案件，也是艾滋病毒感染的妇女的第二高。 全国生育年龄。 GU Actu致力于充分 妇女和少数民族参与临床试验以及严格的 研究影响HIV药物方案的科学问题。 作为 艾滋病流行病的人口统计学有变化，与HIV相关的临床试验 在GU越来越多地代表非裔美国人（52％），IVDU和 妇女（21％）。 DC综合医院和惠特曼·沃克诊所将成为Actu 亚基，提供增加对患者人群的访问权限 以及为所有研究患者提供初级保健的能力，从而 鼓励招募和保留。 预计亚基会 我们每年提议的150名患者中有33％。 艾滋病毒的治疗 淋巴瘤是GU特别重点的区域。发展和 新的化学治疗方法应用于艾滋病毒相关的 将研究恶性肿瘤。 马里兰州医疗实验室公司，ACTG 批准的实验室将负责病毒学核心部分。 可选研究应用程序在药理学领域提交， 流行病学和免疫学。 药理学核心支持实验室 提出了对导致不良药物影响因素的调查 以及包括遗传和代谢预测因素在内的相互作用。 一个项目 根据C.6的资金提出的建议将评估心理心理的影响， 临床依从性和保留性的生物学和医疗因素 试验，解决可能影响审判建议的问题 涉及处境不利或服务不足的人群的设计。 正在进行的工作 在控制雄性分枝杆菌内的免疫学上将是 扩展，特别关注NK细胞功能的重要性。 来自可选组件的数据将对治疗剂产生影响 和试用设计。 与VA建立了合作 医院的CPCRA网站和HRSA HIV示范项目。 他们会的 与GU和霍华德大学医学中心一起参加 社区外展计划，以对不足的团体进行教育 他们参与临床试验的优势和重要性。 这 乔治敦Actu应用程序代表了现有的专业知识 华盛顿，我们社区的多样性，以及科学询问 主要大学医学中心。